CHU Dijon Bourgogne Hôpital François Mitterand
- Address
- 14 rue Gaffarel, 21000 Dijon, France
CHU Dijon Bourgogne Hôpital François Mitterand - Specialized Research Center
CHU Dijon Bourgogne Hôpital François Mitterand is a comprehensive university hospital center engaged in advanced clinical research across multiple therapeutic domains. The center demonstrates particular expertise in cardiovascular-pulmonary disorders, infectious diseases, and oncology, contributing to innovative treatment approaches for complex medical conditions.
- Chronic thromboembolic pulmonary hypertension (CTEPH) with focus on combination oral therapies and pulmonary vascular resistance management
- Community-acquired pneumonia and acute respiratory tract infections with adaptive platform trial methodologies
- Advanced melanoma immunotherapy and combination treatment strategies for metastatic skin cancers
The research portfolio reflects a commitment to personalized medicine and multi-factorial treatment approaches. The center's involvement in international platform trials and innovative drug combination studies demonstrates its role in shaping treatment paradigms for both rare vascular conditions and more prevalent respiratory infections. Their oncology research particularly emphasizes immunotherapy enhancement strategies for patients with advanced melanoma who have limited treatment options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 70 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Dijon Bourgogne Hôpital François Mitterand
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 70 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 3 | Unknown | 2024-02-21 | 2024-11-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.